Immunological responses after concomitant vaccination with the yellow fever-vaccine and the TBE-vaccine, or JE-vaccine
- Conditions
- Prevention of TBE or Japanece encephalitis by co-vaccination with the yellow fever vaccineTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2017-002137-32-SE
- Lead Sponsor
- Hans-Gustaf Ljunggren
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 140
Individuals that need prevention of TBE, Yellow fever and JE
Induviduals that signed informed concent
Individuals between 18-55 years of age
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 140
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Individuals that:
Claim that they already had vaccination, or been infected with TBE, JE or Yellow fever
Are allergic to eggs or something else in FSME Immun, Stamaril and Ixiaro
Have an autoimmune disease
Have difficulties donating blood
Take drugs against cancer
Take corticosteroids
Have a disease that had affected the brain
Have neurological disorders
Have dampened immune function or that of other reason is evaluated by the investigator as inappropriate for inclusion
Have HCV or HIV
Had fever within a week from the time of vaccination
Are pregnant or plan to be pregnant in the course of the study
Have a bleeding disorder
Breastfeed
Participated in other clinical trials within the last three months
Cannot fulfill the study
Or for other reasons is evaluated not to be suitable for inclusion
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method